Ultrasound Guided Rhomboid Intercostal and Subserratus Plane Block in Breast Cancer Surgeries

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04336917

Enrollment

Registered

2020-04-07

Start date

2020-08-31

Completion date

2021-03-01

Last updated

2021-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer Surgery, Postoperative Analgesia

Keywords

Rhomboid intercostal and subserratus plane block

Brief summary

Postoperative analgesia after breast cancer surgery is a challenge for anesthesiologists due to the complex innervation of the breast. Interfascial plane blocks of the chest are gaining widespread popularity with the introduction of ultrasonography into the regional anesthesia practice. We aimed to investigate the efficacy of Rhomboid intercostal and subserratus plane block (RISS) for postoperative analgesia in patients undergoing breast cancer surgery.

Detailed description

This prospective randomized controlled trial will be carried out on female patients who scheduled for breast cancer surgery. Our hypotesis is that this new interfascial plane block technique will able to provide postoperative analgesia in breast cancer surgery.

Interventions

DRUGRhomboid Intercostal and Subserratus Plane Block with local anesthetic

Local anesthetic will be injected in the tissue planes between the rhomboid and the intercostal muscles and the serratus anterior and external intercostal muscles with ultrasound guidence.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Intervention model description

Prospective study

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

* Female patients aged 18-85 years and ASA physiological score I-III who undergone breast cancer surgery

Exclusion criteria

* Patients refused to participate. * Patients with known or suspected allergy to the used medication. * Patients with psychiatric-neurological disorders that may affect pain perception, * Patients regularly taking antipsychotics and antidepressants. * Patients with potential risk of coagulopathy. * Uncooperative patients.

Design outcomes

Primary

Measure	Time frame	Description
Postoperative opiod consumption	The first 24 hours postoperatively	Opioid consumptions for both group will be recorded.

Secondary

Measure	Time frame	Description
Postoperative pain scores	The first 24 hours postoperatively	Postoperative pain will be assessed using a Numeric Rating Scale (NRS) ranging from 0 (no pain) to 10 (worst imaginable pain).The NRS will be recorded in postoperative unit and in ward at first hour and at 2th, 6th, 12th and 24 th hour.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026